Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy.
Llobet says PQ Grass met its primary endpoint, with those taking the drug showing “a highly statistically significant” reduction in symptoms compared to patients in the placebo arm of the study.
Original Article: Allergy Therapeutics on track for phase III grass pollen trial in 2019